Alice Paulitti

Alice Paulitti

Auto-generated profile, based on publicly available information

Alice Paulitti

Department of Research and Diagnosis, Division of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2013 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
SMStefano Marastoni
Stefano Marastoni
EAEva Andreuzzi
Eva Andreuzzi
APAlice Paulitti
Alice Paulitti
RCRoberta Colladel
Roberta Colladel
RPRosanna Pellicani
Rosanna Pellicani
Maurizio MongiatMaurizio Mongiat
Maurizio Mongiat

10 September 2015 in Blood
Verified
Journal Article
Closed access
PDF file
MCMarta Celegato
Marta Celegato
CBCinzia Borghese
Cinzia Borghese
NCnaike casagrande
naike casagrande
Maurizio MongiatMaurizio Mongiat
Maurizio Mongiat
XKXaver U. Kahle
Xaver U. Kahle
Donatella AldinucciDonatella Aldinucci
Donatella Aldinucci

11 February 2022 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EAEva Andreuzzi
Eva Andreuzzi
AFAlbina Fejza
Albina Fejza
MPMaurizio Polano
Maurizio Polano
EPEvelina Poletto
Evelina Poletto
LCLucrezia Camicia
Lucrezia Camicia
Maurizio MongiatMaurizio Mongiat
Maurizio Mongiat
Background: Colorectal cancer is one of the most frequent and deadly tumors. Among the key regulators of CRC growth and progression, the microenvironment has emerged as a crucial player and as a possible route for the development of new therapeutic opportunities. More specifically, the extracellular matrix acts directly on cancer cells and indirectly affecting the behavior of stromal and inflammatory cells, as well as the bioavailability of growth factors. Among the ECM molecules, EMILIN-2 is frequently down-regulated by methylation in CRC and the purpose of this study was to verify the impact of EMILIN-2 loss in CRC development and its possible value as a prognostic biomarker. Methods: The AOM/DSS CRC protocol was applied to Emilin-2 null and wild type mice. Tumor development was monitored by endoscopy, the molecular analyses performed by IHC, IF and WB and the immune subpopulations characterized by flow cytometry. Ex vivo cultures of monocyte/macrophages from the murine models were used to verify the molecular pathways. Publicly available datasets were exploited to determine the CRC patients’ expression profile; Spearman’s correlation analyses and Cox regression were applied to evaluate the association with the inflammatory response; the clinical outcome was predicted by Kaplan-Meier survival curves. Pearson correlation analyses were also applied to a cohort of patients enrolled in our Institute. Results: In preclinical settings, loss of EMILIN-2 associated with an increased number of tumor lesions upon AOM/DSS treatment. In addition, in the early stages of the disease, the Emilin-2 knockout mice displayed a myeloid-derived suppressor cells-rich infiltrate. Instead, in the late stages, lack of EMILIN-2 associated with a decreased number of M1 macrophages, resulting in a higher percentage of the tumor-promoting M2 macrophages. Mechanistically, EMILIN-2 triggered the activation of the Toll-like Receptor 4/MyD88/NF-κB pathway, instrumental for the polarization of macrophages towards the M1 phenotype. Accordingly, dataset and immunofluorescence analyses indicated that low EMILIN-2 expression levels correlated with an increased M2/M1 ratio and with poor CRC patients’ prognosis. Conclusions: These novel results indicate that EMILIN-2 is a key regulator of the tumor-associated inflammatory environment and may represent a promising prognostic biomarker for CRC patients.

9 December 2015 in Oncotarget
Verified
Journal Article
Open access
RCRoberta Colladel
Roberta Colladel
RPRosanna Pellicani
Rosanna Pellicani
EAEva Andreuzzi
Eva Andreuzzi
APAlice Paulitti
Alice Paulitti
GTGiulia Tarticchio
Giulia Tarticchio
Maurizio MongiatMaurizio Mongiat
Maurizio Mongiat
MULTIMERIN2 binds VEGF-A primarily via the carbohydrate chains exerting an angiostatic function and impairing tumor growth